ProCE Banner Activity

Ponatinib After Progression on Second-Generation TKI Therapy in Chronic-Phase Chronic Myeloid Leukemia: Combined Analysis of PACE and OPTIC

Slideset Download
Conference Coverage
Ponatinib treatment in patient with chronic-phase chronic myeloid leukemia who progressed after second-generation TKIs showed efficacy and tolerability in this pooled analysis of the PACE and OPTIC trials.

Released: December 15, 2020

Expiration: December 14, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology